IPCA Laboratories Limited Q4 results show revenue fell from 1,576.89 to 1,548.02 crores, a 1.83% decrease in growth. EPS also dropped from ₹4.25 to ₹3.02, down by 28.94%.
First, Let’s Begin with Quarter-on-Quarter Basis:
IPCA Laboratories Ltd. shared its Q4 results on Monday. They earned 1,548.02 crores in revenue this quarter, but that’s less than the 1,576.89 crores they made last quarter. Unfortunately, the company’s growth decreased by 1.83 percent when comparing the two quarters.
In terms of profits, the company’s Consolidated PAT (Profit After Tax) for this quarter was 76.52 crores, down from 107.84 crores in the previous quarter. Their quarter-to-quarter growth declined by 29.04 percent.
The company’s EPS (Earnings Per Share) this quarter is ₹3.02, which is a decrease of 28.94% from the ₹4.25 EPS in the previous quarter.
Now, Let’s Analyze the Results on a Year-over-Year Basis:
The company made a total revenue of 6,369.94 crores this year (2023), which is 8.03 percent higher than last year’s total revenue of 5,896.36 crores.
This year’s PAT (Profit After Tax) is 471.32 crores, which is also 46.69% lower than last year’s PAT of 884.08 crores.
The EPS (Earnings Per Share) for this year is ₹18.58, which is 46.69% less than the EPS of ₹34.85 earned last year.
IPCA Laboratories Share Dividend Announcement / Record Date:
Not related to distributing a portion of a company’s earnings to shareholders in the form of cash or stock dividends. ( No Dividend Payout )
About IPCA Laboratories:
Ipca Laboratories Limited is a Mumbai multinational pharmaceutical company. The company specializes in the production of active pharmaceutical ingredients (APIs) such as theobromine, acetylthiophene, and p-bromotoluene. the company sells these APIs and their intermediates worldwide, catering to a global market.
Download the Full PDF of Q4 Results: Click Here
For more of the Latest News, Click Here